Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) EPS (Basic) (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of EPS (Basic) data on record, last reported at -$0.33 in Q4 2025.

  • For Q4 2025, EPS (Basic) rose 1.75% year-over-year to -$0.33; the TTM value through Dec 2025 reached -$0.33, up 71.93%, while the annual FY2025 figure was -$0.87, 26.89% up from the prior year.
  • EPS (Basic) reached -$0.33 in Q4 2025 per TNGX's latest filing, up from -$0.35 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.09 in Q2 2021 and bottomed at -$0.36 in Q1 2025.
  • Average EPS (Basic) over 5 years is -$0.29, with a median of -$0.29 recorded in 2021.
  • The widest YoY moves for EPS (Basic): up 69.52% in 2021, down 7166.4% in 2021.
  • A 5-year view of EPS (Basic) shows it stood at -$0.28 in 2021, then decreased by 17.86% to -$0.33 in 2022, then grew by 9.09% to -$0.3 in 2023, then fell by 13.33% to -$0.34 in 2024, then rose by 1.75% to -$0.33 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.33 in Q4 2025, -$0.35 in Q2 2025, and -$0.36 in Q1 2025.